Sagimet Biosciences Inc. (SGMT) earnings date
Mar 10, 2027, before open estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 40% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 44 days, typically, give or take 13 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | before open | 43 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | before open | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | before open | 42 | 8-K |
| Q4 FY2025 | Wed, Mar 11, 2026 | before open | 70 | 8-K |
| Q3 FY2025 | Thu, Nov 13, 2025 | before open | 44 | 8-K |
| Q2 FY2025 | Wed, Aug 13, 2025 | before open | 44 | 8-K |
| Q1 FY2025 | Thu, May 8, 2025 | before open | 38 | 8-K |
| Q4 FY2024 | Wed, Mar 12, 2025 | before open | 71 | 8-K |
What they guided beta
| Q3 FY2026 | "Pro forma cash and investments balance of approximately $356 million as of September 30, expected to fund current operations through mid-2029 including through readout of data from the denifanstat AURORA Phase 3 clinical trial in moderate to severe acne and potential NDA submission" exhibit |
| Q3 FY2026 | "The trial is intended to support a potential U.S. New Drug Application (NDA), with topline data expected in the second half of 2027." exhibit |
| Q3 FY2026 | "Phase 2 doses have been identified, and the Company anticipates initiating the Phase 2 clinical trial of TVB-3567 in moderate to severe acne patients before the end of 2026." exhibit |
| Q3 FY2026 | "Fall Clinical Dermatology 2026: In October 2026, Sagimet presented the positive 52-week results from Ascletis’ Phase 3 open-label extension trial, previously presented by Ascletis at EADV 2026, together with mechanistic data supporting denifanstat’s differentiated approach to targeting key aspects of acne pathogenesis: sebum production and inflammation ( here )." exhibit |
| Q3 FY2026 | "Denifanstat: Continue enrollment in the U.S. AURORA Phase 3 clinical trial in moderate to severe acne, with topline data expected in the second half of 2027." exhibit |
| Q2 FY2026 | "Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Secured equity financing with gross proceeds of $175.0 million in April 2026 Cash, cash equivalents and marketable securities of $257.6 million as of June 30, 2026, expected to fund current operations through 2028, including through data readout of denifanstat Phase 3 trial in moderate to sev" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/SGMT
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/SGMT
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/SGMT/"><img src="https://veritasdata.dev/embed/SGMT.svg" alt="SGMT earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/SGMT/)
Script
<script async src="https://veritasdata.dev/embed/SGMT.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/SGMT"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.